# Reply to: Response and remission in asthma with tezepelumab: overlapping concepts informing on type-2 inflammatory-dependent treatment effects

## TL;DR

The study discusses how tezepelumab treatment affects asthma patients, focusing on clinical remission and response linked to inflammation levels.

## Contribution

The paper clarifies the relationship between baseline inflammation and treatment outcomes in asthma patients using tezepelumab.

## Key findings

- Clinical remission with tezepelumab is associated with high baseline inflammatory biomarkers.
- Patients achieving remission had less severe disease at baseline compared to those with complete clinical response.

## Abstract

We thank S. Mailhot-Larouche and co-workers for their interest in our recent publication on clinical response and clinical remission with tezepelumab treatment, reporting results over 2 years from patients with severe, uncontrolled asthma enrolled in the NAVIGATOR and DESTINATION clinical trials [1].

Achieving on-treatment clinical remission with tezepelumab was associated with high baseline inflammatory biomarkers, but those achieving remission were observed to have less severe disease at baseline than those who achieved complete clinical response
https://bit.ly/3P0C52q